Navigation Links
febit and TGen Collaborate to Study New DNA Capture Method
Date:8/14/2008

febit's HybSelect(TM) Technology Evaluated to Enable Targeting and Increase

Speed for Next-Generation-Sequencing

LEXINGTON, Mass. and HEIDELBERG, Germany, Aug. 14 /PRNewswire/ -- febit and the Translational Genomics Research Institute (TGen) today announced the formation of a collaboration in which TGen will evaluate Next-Generation-Sequencing equipment in conjunction with febit's proprietary Geniom(R) Microarray Technology.

febit's HybSelect(TM) Technology enables selective DNA capture and elution, an extremely efficient method to preselect sequences for Next-Generation Sequencers. HybSelect is based on febit's proven Geniom Technology and uses arrays within microfludic biochips for the selection process of targeted DNA. Geniom biochips are programmable and can contain any desired set of capture probes. The new method combines the extraordinary performance of latest sequencers with the efficient selection capabilities of Geniom Technology.

"We are delighted to have TGen as our first U.S. pilot user of HybSelect with the latest sequencing instrumentation," said Cord F. Staehler, president of febit. "We will obtain important data from TGen that will help us as we prepare for the official introduction of HybSelect in early 2009." The collaboration provides TGen scientists pre-market access to a highly developed DNA capturing method.

"There's been a great deal of conversation on the future direction of genomic research centers on next generation sequencing," said Matthew Huentelman, Ph.D., TGen associate investigator and lead collaborator on this project. "This collaboration on the use and further development of this method enhances the opportunities for TGen researchers to make a difference in research utilizing next generation sequencing."

TGen has been a user of the Geniom One device for the production and microarray analysis of Geniom Biochips since 2006.

About febit

febit enables scientists to read, write and understand the code of life: DNA. With its unique Geniom technology and services, febit is the only company that puts the control of simplified genomic research in the hand of the user. The seamless integration of DNA synthesis and analysis and the superior support in experiment design and bioinformatics helps to understand data and turn it into results. febit's team of experienced scientists is dedicated to support customers to solve the challenge of understanding biological processes. Geniom is a technological and service platform successfully implemented in basic and applied research by renowned institutions and companies. Geniom exploits cutting-edge microarray technology for analysis and synthesis of genes and genomes, providing superior time- and cost-efficiency combined with an unsurpassed spectrum of applications.

http://www.febit.com

About TGen

The Translational Genomics Research Institute (TGen) is a non-profit 501(c)(3) organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen's vision is of a world where an understanding of genomic variation can be rapidly translated in a manner tailored to individual patients.
http://www.tgen.org

Contact:

febit holding gmbh Russo Partners, LLC

Eva Sterzel David Schull or Wendy Lau

Public Relations Manager +1-212-845-4271

+49 (6221) 6510-300 david.schull@russopartnersllc.com

mail to: eva.sterzel@febit.de wendy.lau@russopartnersllc.com


'/>"/>
SOURCE febit
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
2. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
3. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
4. DuPont and USDA ARS to Collaborate on New E. coli Test in Beef
5. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
6. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
7. The Leukemia & Lymphoma Society and Memgen Collaborate on CLL Clinical Trial
8. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
9. Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... India , April 28, 2016 ... Pipeline Review, H1 2016" is a report that ... and helps strengthen R&D pipelines by identifying new ... products. Company Profiles discussed in this ... Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
(Date:4/27/2016)... April 27, 2016 Tie-up with ... initiative to save newborns   Fortis ... & newborns in collaboration with Breast Milk Foundation (BMF), a ... Pasteurized Human Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit ... source for infants and should be available to babies deprived ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... A new study by a ... diaphragmatic hernia have better survival rates if surgery is performed early. Approximately one ... the diaphragm fails to form completely, letting abdominal organs into the chest cavity ...
(Date:4/29/2016)... ... 2016 , ... The Wharton School of the University ... of the 2016 Wharton Business Plan Competition —as well as the Wharton ... the Committee Award for Most ‘Wow Factor,’ making them the first team in ...
(Date:4/29/2016)... ... 29, 2016 , ... World Patent Marketing , a ... invention which aids in proper muscle development. , "The Gym & Exercise Equipment ... of World Patent Marketing. "Globalization has threatened the future growth of the industry ...
(Date:4/29/2016)... ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although ... the majority of skin cancer deaths. More than 10,000 people are expected to die of ... is 62, it is the one of the most commonly diagnosed cancers in young women. ...
(Date:4/29/2016)... , ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon ... is a very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to ... is a procedure that involves one or both jaw bones. This surgery is performed to ...
Breaking Medicine News(10 mins):